PET/CT Imaging for Heart Function in Lung Cancer
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Thomas Jefferson University
Disqualifiers: Contraindication for FDG PET-CT, others
No Placebo Group
Trial Summary
What is the purpose of this trial?This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of PET/CT imaging for heart function in lung cancer treatment?
PET/CT imaging, which combines two types of scans, has been shown to be very useful in diagnosing and staging lung cancer, predicting how well a treatment might work, and assessing the aggressiveness of tumors. This imaging technique helps in early diagnosis and can guide treatment decisions, potentially improving patient outcomes.
12345Is PET/CT imaging safe for humans?
PET/CT imaging is generally considered safe for humans, as it is a widely used diagnostic tool. However, like any medical procedure, it may have some risks, such as exposure to radiation, but these are typically low and managed carefully in clinical settings.
678910How does PET/CT imaging differ from other treatments for lung cancer?
PET/CT imaging is unique because it combines two types of scans to provide both detailed pictures and information about the activity of cancer cells, helping in the diagnosis, staging, and management of lung cancer more effectively than traditional imaging methods.
15111213Eligibility Criteria
This trial is for adults with pathologically confirmed lung cancer who are about to undergo radiation therapy and have a life expectancy of at least 3 months. They must consent to the study's procedures, be available throughout, and receive a heart dose of radiation estimated at 5 Gy or more. It excludes those on palliative radiation doses or with contraindications for FDG PET-CT scans.Inclusion Criteria
I am 18 years old or older.
Provide signed and dated informed consent form
Life expectancy >= 3 months as assessed by Radiation Oncologist
+4 more
Exclusion Criteria
Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
I received a specific low-dose radiation treatment.
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Radiation Therapy
Patients undergo radiation therapy as part of their cancer treatment
Varies based on individual treatment plans
Multiple visits for radiation sessions
Imaging
Patients undergo sarcoidosis FDG PET-CT of the heart before, during, and after radiotherapy to monitor changes
Concurrent with radiation therapy
3 visits for imaging (before, during, after radiotherapy)
Follow-up
Participants are monitored for safety and effectiveness after treatment
24 months
Follow-up visits at 12 and 24 months
Participant Groups
The EUCLID Trial is testing the use of PET/CT imaging to detect potential cardiac damage from radiation treatment in lung cancer patients. The goal is to monitor heart function before, during, and after radiotherapy using this imaging technique which can highlight inflammation and tissue viability.
1Treatment groups
Experimental Treatment
Group I: Diagnostic (sarcoidosis FDG PET-CT)Experimental Treatment4 Interventions
Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Thomas Jefferson University HospitalPhiladelphia, PA
Loading ...
Who Is Running the Clinical Trial?
Thomas Jefferson UniversityLead Sponsor
References
Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine. [2022]With a 5-year overall survival of approximately 20%, lung cancer has always been the number one cancer-specific killer all over the world. As a fusion of positron emission computed tomography (PET) and computed tomography (CT), PET/CT has revolutionized cancer imaging over the past 20 years. In this review, we focused on the optimization of the function of 18F-flurodeoxyglucose (FDG)-PET/CT in diagnosis, prognostic prediction and therapy management of lung cancers by computer programs. FDG-PET/CT has demonstrated a surprising role in development of therapeutic biomarkers, prediction of therapeutic responses and long-term survival, which could be conducive to solving existing dilemmas. Meanwhile, novel tracers and optimized procedures are also developed to control the quality and improve the effect of PET/CT. With the continuous development of some new imaging agents and their clinical applications, application value of PET/CT has broad prospects in this area.
Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. [2022]Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-D-glucose, complements conventional imaging evaluation of patients with lung cancer. The strength of PET scanning lies in the detection of nodal and extrathoracic metastases. PET scanning is also currently being studied in the assessment of prognosis and therapeutic response and has the potential to alter management of oncologic patients. This review will discuss the role of PET/computed tomographic scanning in the diagnosis, staging, and evaluation of prognosis and treatment response in patients with lung cancer.
Association of Receipt of Positron Emission Tomography-Computed Tomography With Non-Small Cell Lung Cancer Mortality in the Veterans Affairs Health Care System. [2020]Positron emission tomography-computed tomography (PET-CT) has been increasingly used in the management of lung cancer, but its association with survival has not been convincingly documented.
[The use of FDG-PET scanning in lung cancer]. [2016]Positron emission tomography (PET) imaging with fluorodeoxyglucose (FDG) is a very useful imaging modality that significantly contributes to the diagnosis and staging in patients with lung cancer. Additionally, FDG-PET has been shown to play an effective role to predict therapy response and to assess tumor aggressiveness as well as to define radiotherapy treatment fields. Further technologic improvements in PET scanners and new more tumor specific radiopharmaceuticals are likely to bring further benefits to the management of patients with lung cancer in the future.
[Contribution of PET using FDG in the diagnosis of lung cancer--first results]. [2016]Positron emission tomography (PET), when used with F-18 fluoro-deoxyglucose (FDG), contributes to the evaluation of patients with lung cancer. This technique of imaging detects active tumor tissue by showing increased radiopharmaceutical uptake by metabolically active cells. Thus, PET assists in the early diagnosis of pulmonary malignancies that appear only as non-specific findings on CT-scan or chest X-ray. In addition, it is helpful in staging lung cancer before and after resection, chemotherapy or radiotherapy, or their combined use. We performed 135 FDG-PET studies between July '97-April '99 and present our preliminary results with examples of the main indications for PET in lung cancer.
Prognostic value of early left ventricular ejection fraction reserve during regadenoson stress solid-state SPECT-MPI. [2022]We hypothesized early post-stress left ventricular ejection fraction reserve (EFR) on solid-state-SPECT is associated with major cardiac adverse events (MACE).
Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging. [2023]Late adverse cardiac events after radiation therapy (RT) for thoracic malignancies are known, but the underlying mechanisms are poorly understood. This study aimed to determine the radiation dose that can cause MBF alterations in the subacute phase after RT for thoracic esophageal cancer using stress dynamic myocardial computed tomography perfusion imaging (CTP).
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. [2022]Purpose The significance of radiotherapy (RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study. We assessed the impact of heart dose in patients treated at our institution on several prospective dose-escalation trials. Patients and Methods From 1996 to 2009, 127 patients with stage III NSCLC (Eastern Cooperative Oncology Group performance status, 0 to 1) received dose-escalated RT to 70 to 90 Gy (median, 74 Gy) in six trials. RT plans and cardiac doses were reviewed. Records were reviewed for the primary end point: symptomatic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, significant arrhythmia, and heart failure). Cardiac risk was assessed by noting baseline coronary artery disease and calculating the WHO/International Society of Hypertension score. Competing risks analysis was used. Results In all, 112 patients were analyzed. Median follow-up for surviving patients was 8.8 years. Twenty-six patients (23%) had one or more events at a median of 26 months to first event (effusion [n = 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmia [n = 12], and heart failure [n = 1]). Heart doses (eg, heart mean dose; hazard ratio, 1.03/Gy; P = .002,), coronary artery disease ( P
Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era. [2019]Cardiac positron emission testing (PET) is more accurate than single photon emission computed tomography (SPECT) at identifying coronary artery disease (CAD); however, the 2 modalities have not been thoroughly compared in a real-world setting. We conducted a retrospective analysis of 60-day catheterization outcomes and 1-year major adverse cardiovascular events (MACE) after the transition from a SPECT- to a PET-based myocardial perfusion imaging (MPI) program.
Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL). [2022]In patients with locally advanced non-small cell lung cancer (LA-NSCLC) post-radiotherapy, mean heart dose (MHD) and the percent of left anterior descending (LAD) coronary artery receiving ≥15 Gy (LADV15) are associated with major adverse cardiac events (MACE). We developed a MACE prediction model in this population.
[Positron emission tomography/computed tomography for lung cancer staging]. [2016]PET/CT (Positron Emission Tomography/Computed Tomography) is widely used in nodal and metastatic staging of lung cancer patients.
[Diagnosis of lung cancer. Role of PET/CT fusion scan in lung cancer]. [2007]Whole-body positron emission tomography (PET) with radiolabeled [18F]-fluoro-2-deoxy-D-glucose (18FDG) plays an important role in the diagnosis, staging, and management of lung cancer. The preferential accumulation of FDG in malignant cells assists in the differentiation of benign and malignant tissue. However, PET alone does not allow an accurate anatomic localisation of FDG uptake. The combination of PET with CT images improves the spatial resolution, sensitivity and specificity of the test. PET/CT, as with PET alone, is indicated for the diagnosis of pulmonary nodules as well as the locoregional and extrathoracic staging of non-small-cell lung cancer (NSCLC). In many published studies, PET/CT has been shown to be superior to CT alone, to PET alone, or to both imaging techniques used separately to evaluate pulmonary nodules or for staging NSCLC. Now, PET/CT imaging is being investigated in the staging and management of small-cell lung cancer, in radiation treatment planning, in response prediction following treatment and in the detection of lung cancer recurrence in NSCLC. PET/CT is likely to have an important role in the management of lung cancer. New machines are in development and new radiopharmaceutical agents must be assessed.
Role of positron emission tomography-computed tomography in pulmonary neoplasms. [2016]Positron emission tomography (PET)-computed tomography (CT) has become a routine imaging modality in body oncology and is particularly well suited for the management of patients with lung cancer. Current clinical applications of PET-CT in patients with lung cancer include evaluation of indeterminate pulmonary nodules, initial staging of lung cancer, restaging of lung cancer following treatment, and radiation therapy planning. Contemporary PET-CT scanners allow comprehensive diagnostic PET and CT imaging in a single imaging session. Interpretation and reporting of PET-CT examinations of patients with lung cancer require a thorough and integrated approach taking advantage of the anatomic and metabolic information.